phenyl acetate has been researched along with iloprost in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (54.55) | 18.2507 |
| 2000's | 1 (9.09) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brassard, CL; Buchanan, JO; Gougoutas, JZ; Malley, MF; Martin, SW; Meanwell, NA; Romine, JL; Rosenfeld, MJ; Trehan, AK; Wright, JJ | 1 |
| Wise, H | 2 |
| Brassard, CL; Federici, ME; Meanwell, NA; Romine, J; Seiler, SM | 1 |
| Chan, HW; Ho, JK; Jones, RL; Lam, WL; Qian, YM; Wise, H; Wong, HN; Yim, AP | 1 |
| Chow, KB; Wise, H | 1 |
| Chow, KB; Wise, H; Wong, YH | 1 |
| Ankarali, H; Cicek, OF; Erdem, H; Gedik, HS; Kaya, E; Korkmaz, K; Lafci, G; Nacar, OA; Yildirim, L | 1 |
| Benyahia, C; Boukais, K; Clapp, L; Danel, C; Fabre, A; Gomez, I; Leséche, G; Longrois, D; Norel, X; Silverstein, A | 1 |
| Clapp, LH; Ledwozyw, A; Orie, NN; Whittle, BJ; Williams, DJ | 1 |
| Clozel, M; Gatfield, J; Gnerre, C; Hess, P; Iglarz, M; Menyhart, K; Monnier, L; Morrison, K; Nayler, O; Wanner, D | 1 |
11 other study(ies) available for phenyl acetate and iloprost
| Article | Year |
|---|---|
Nonprostanoid prostacyclin mimetics. 5. Structure-activity relationships associated with [3-[4-(4,5-diphenyl-2-oxazolyl)-5- oxazolyl]phenoxy]acetic acid.
Topics: Acetates; Adenosine Diphosphate; Binding, Competitive; Crystallization; Epoprostenol; Humans; Hydrogen Bonding; Iloprost; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Structure; Oxazoles; Platelet Aggregation; Platelet Aggregation Inhibitors; Receptors, Epoprostenol; Receptors, Prostaglandin; Structure-Activity Relationship | 1993 |
The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function.
Topics: Acetates; Animals; Calcium; Cell Aggregation; Cyclic AMP; Drug Design; Epoprostenol; Glyburide; Iloprost; Imidazoles; Male; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Oxazoles; Phenoxyacetates; Phosphodiesterase Inhibitors; Prostaglandins, Synthetic; Rats; Rats, Sprague-Dawley; Receptors, Prostaglandin | 1996 |
[3-[4-(4,5-Diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY 45778) is a potent non-prostanoid prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding.
Topics: Acetates; Adenylyl Cyclases; Animals; Binding, Competitive; Cell Membrane; Cyclic AMP; Epoprostenol; GTP Phosphohydrolases; Humans; Iloprost; Imidazoles; Oxazoles; Phenoxyacetates; Platelet Aggregation Inhibitors; Protein Kinases; Rabbits; Rats | 1997 |
Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
Topics: Acetates; Aged; Cardiovascular Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoprostenol; Fatty Acids; Humans; Iloprost; Imidazoles; Indoles; Middle Aged; Muscle, Smooth, Vascular; Oxazoles; Phenoxyacetates; Platelet Aggregation Inhibitors; Prostaglandins, Synthetic; Pulmonary Artery; Receptors, Epoprostenol; Receptors, Prostaglandin; Structure-Activity Relationship; Vasoconstrictor Agents; Vasodilator Agents | 1997 |
The effect of prostacyclin mimetics on neutrophil function.
Topics: Acetates; Animals; Cell Aggregation; Cyclic AMP; Epoprostenol; Iloprost; Imidazoles; Isoquinolines; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Oxazoles; Peritoneal Cavity; Phenoxyacetates; Pyrrolidinones; Rats; Rolipram; Second Messenger Systems; Sulfonamides | 1997 |
The effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells.
Topics: Acetates; Cell Line; Cyclic AMP; Epoprostenol; Humans; Iloprost; Imidazoles; Kinetics; Neuroblastoma; Neurons; Oxazoles; Phenoxyacetates | 1997 |
Prostacyclin receptor-independent inhibition of phospholipase C activity by non-prostanoid prostacyclin mimetics.
Topics: Acetates; Adenylyl Cyclases; Alprostadil; Animals; Cell Survival; CHO Cells; Cricetinae; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epoprostenol; Iloprost; Imidazoles; Inositol Phosphates; Oxazoles; Phenoxyacetates; Pyridines; Receptors, Epoprostenol; Receptors, Prostaglandin; Transfection; Tritium; Type C Phospholipases | 2001 |
Efficacy of iloprost and montelukast combination on spinal cord ischemia/reperfusion injury in a rat model.
Topics: Acetates; Animals; Biomarkers; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Iloprost; Injections, Intraperitoneal; Male; Neuroprotective Agents; Oxidative Stress; Quinolines; Random Allocation; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Spinal Cord; Spinal Cord Injuries; Sulfides; Treatment Outcome | 2013 |
A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor.
Topics: Acetates; Aged; Drug Evaluation, Preclinical; Epoprostenol; Female; Humans; Iloprost; In Vitro Techniques; Inhibitory Concentration 50; Male; Middle Aged; Molecular Mimicry; Pulmonary Artery; Pulmonary Veins; Pyrazines; Receptors, Epoprostenol; Receptors, Immunologic; Receptors, Prostaglandin; Receptors, Prostaglandin E, EP4 Subtype; Vasodilation; Vasodilator Agents | 2013 |
Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Topics: Acetamides; Acetates; Animals; Benzofurans; Benzyl Compounds; Epoprostenol; Female; Iloprost; Imidazoles; Male; Propionates; Pulmonary Artery; Pulmonary Veins; Pyrazines; Rats; Rats, Sprague-Dawley; Receptors, Epoprostenol; Vasodilation | 2013 |
Selexipag Active Metabolite ACT-333679 Displays Strong Anticontractile and Antiremodeling Effects but Low
Topics: Acetamides; Acetates; Animals; beta-Arrestins; Cell Proliferation; CHO Cells; Contractile Proteins; Cricetinae; Cricetulus; Cyclic AMP; Epoprostenol; Extracellular Matrix; Humans; Hypertension, Pulmonary; Iloprost; Male; Muscle Contraction; Muscle Relaxation; Pyrazines; Rats; Rats, Inbred SHR; Rats, Wistar; Receptors, Epoprostenol | 2017 |